BiotechTube
Metfora

Metfora

Cambridge, United States· Est.
metfora.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Metfora is an early-stage diagnostics company founded in 2021 and based in Cambridge, Massachusetts. It is developing a blood-based metabolomic test designed to detect serious chronic diseases, such as COPD and pulmonary hypertension, at early stages using a proprietary metabolite analysis platform. The company has initiated regulatory discussions with the FDA for its lead test, ExpertLungDx, targeting a significant unmet need in reducing diagnostic delays. Its business model is centered on providing actionable diagnostic insights to healthcare providers and systems.

PulmonologyChronic Lung Diseases

Technology Platform

Proprietary metabolomics platform analyzing circulating metabolites in blood to generate disease-specific metabolic fingerprints for early detection and monitoring of chronic diseases.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive unmet need for early diagnosis of chronic lung diseases, which can take years, creates a large addressable market for a rapid blood test.
The platform's potential extends beyond symptomatic diagnosis to treatment monitoring and screening in primary care, enabling a recurring revenue model and integration into value-based healthcare systems.

Risk Factors

Key risks include the need for robust clinical validation to prove test accuracy, navigating a complex FDA regulatory pathway, and securing insurance reimbursement post-approval.
Competition from larger diagnostics firms and the challenge of changing physician behavior for adoption are additional commercial hurdles.

Competitive Landscape

Metfora operates in the competitive space of liquid biopsy and multi-omics diagnostics. While large players like Quest and LabCorp have broad capabilities, and biotech firms like SomaLogic or Nightingale Health focus on proteomics/metabolomics for disease risk, Metfora's narrow, deep focus on early detection of specific chronic lung diseases may differentiate it. However, it will compete for clinical adoption and payer attention.

More companies in Diagnostics & Precision Medicine →More companies in United States →